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Introduction: The aim of this study was to evaluate the relationship between adipokines 
and arterial stiffness in a group of 85 elderly subjects and the role of leptin and adiponectin 
on subclinical vascular damage, defined by a PWV>10 m/s.
Methods: In each subject, we evaluated anthropometry, body composition by DXA (fat 
mass, fat mass%, lean mass), metabolic variables, leptin, adiponectin, systolic, diastolic, 
mean arterial pressure and pulse pressure (SBP, DBP, MAP, PP), carotid-femoral pulse wave 
velocity (cfPWV) and carotid-radial pulse wave velocity (crPWV).
Results: In the study population, significant associations were observed between cfPWV and 
crPWV, age, SBP, MAP, waist circumference, fat body mass and leptin. The study population 
was subdivided in 2 subgroups according to adipokine patterns: group 1 included patients with 
high adiponectin and low leptin, and group 2 patients had high leptin and low adiponectin. SBP, 
PP, cfPWV were significantly higher in subjects with high leptin and low adiponectin (group 2). 
Even after adjustment for gender, fat mass%, MAP, HDL cholesterol and triglycerides, cfPWV 
was higher in group 2 than group 1. In a logistic binary regression on the entire population, 
considering subclinical vascular damage as a dependent variable and age, gender, MAP, fat mass 
%, triglycerides, HDL cholesterol and category of subjects with high leptin and low adiponectin 
as independent variables, MAP and category of subjects with high leptin and low adiponectin 
were significant predictors (OR, respectively, 1.09 and 3.61).
Conclusion: In conclusion, in the elderly, the presence at the same time of high leptin levels 
and low adiponectin levels seems to have synergic effects on arterial stiffness.
Keywords: leptin, adiponectin, elderly, arterial stiffness
Introduction
It has been shown that traditional cardiovascular risk factors such as hypertension, 
obesity, diabetes, dyslipidemia and metabolic syndrome modify the structural and 
functional characteristics of arteries reducing their compliance and increasing 
arterial stiffness.1–4
Several studies showed a significant association between visceral adipose tissue 
(VAT) and increased carotid-femoral pulse wave velocity (cfPWV).3–5 It has been 
proposed that adipokines (as IL-6, plasminogen activating factor inhibitor and 
leptin) may be a link between VAT and endothelial dysfunction.6–8
Among adipokines, adiponectin and leptin have been widely studied because of 
their close relation to fat distribution and cardiovascular risk; their levels also 
change with age even if study results are controversial.9,10 Certainly, leptin- 
resistance, a condition closely related to hyperleptinemia, is higher in elderly and 
age-related fat distribution plays a key role in adipokine panel changes.11,12 
Visceral obesity is associated with hyperleptinemia, leptin-resistance and hypoadi-
ponectinemia configuring a high cardiovascular risk phenotype.13
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Adiponectin and leptin seem to play a key role in the 
regulation of vascular function and in the pathogenesis of 
arterial stiffening and hypertension.14
Moreover, leptin has been proposed as a link between 
obesity and hypertension.15 However, several conditions 
related to obesity such as low-grade inflammation16 and 
insulin resistance17 may influence this association. High 
leptin plasma levels indeed seem to have opposite effects 
activating sympathetic receptors of the central nervous 
system (CNS) and determining vascular smooth muscle 
cell hyperplasia,18 endothelial oxidative stress19 and acti-
vation of renin-angiotensin-aldosterone system (RAAS).20
A large cross-sectional study of 6148 healthy subjects 
showed an association between leptin and PWV. In resis-
tant hypertensive patients plasma leptin concentration was 
associated with arterial stiffness, and leptin levels were 
higher in patients with uncontrolled hypertension.21
On the other hand, adiponectin seems to have vasculo-
protective effects by inducing endothelial e-NOS expression 
and activation,22 suppressing vascular smooth muscle cell 
proliferation and migration23 and repairing injured vessels 
with its interaction with selected molecules in subendothelial 
space and medial wall exposed to the lumen.24
Several cross-sectional studies showed an association 
between hypoadiponectinemia and arterial stiffness.25–27 
A meta-analysis including 17,598 patients found a lower 
level of adiponectin in hypertensive subjects compared 
with non-hypertensives.25 Indeed, two longitudinal studies 
found that baseline adiponectin values were independent 
predictors of aortic stiffness progression measured with 
hfPWV and baPWV.26,27
Finally, Scuteri et al showed that a specific adipokine 
pattern characterized by high levels of leptin in addition to 
low levels of adiponectin could have synergic effect in 
increasing arterial stiffness regardless of traditional cardi-
ovascular risk factor.13
The aim of our study was to evaluate the relationships 
between leptin, adiponectin, body composition and arterial 
stiffness in a group of 85 elderly subjects.
Methods
Subjects
Eighty-five Caucasian subjects (50 women, 35 men) with 
mean age 69.54 ± 4.15 years and mean BMI 26.29 ± 
3.84 kg/m2 took part in the study. The subjects were 
recruited by advertisements in local GPs of Verona, Italy. 
Subjects were eligible if free of known CV diseases and 
did not assume any medications affecting arterial compli-
ance, such as antihypertensive, statin treatment, and hor-
mone replacement therapy. Only post-menopausal women 
were recruited.
All subjects had stable weight during the past 6 
months. None of the subjects was affected by diabetes, 
cancer, or liver, kidney and thyroid diseases, and had no 
evidence of cardiovascular disease (CVD) except hyper-
tension, which was diagnosed after our visit but not known 
at recruitment. Patients with renal impairment (Serum- 
Creatinine > 1.35 mg/dl) were excluded. All subjects 
were non-smokers. The study was approved by the 
Ethical Committee of the University of Verona. The 
study was conducted in accordance with the Declaration 
of Helsinki. All participants gave written informed consent 
to be involved in the research study.
All subjects underwent a careful clinical assessment 
before the study.
Anthropometric Variables
With the subject barefoot and wearing light indoor cloth-
ing, body weight was measured to the nearest 0.1 kg 
(Salus scale, Milan, Italy), and height to the nearest 
0.5 cm using a stadiometer (Salus stadiometer, Milan, 
Italy). BMI was calculated as body weight adjusted by 
stature (kg/m2). Waist circumference was obtained with 
a measuring tape at the level of the narrowest part of the 
torso as viewed anteriorly.
Dual Energy X-Ray Absorptiometry 
(DXA)
Total body fat, trunk and appendicular, legs and total fat- 
free mass (FFM) were determined using a DXA Hologic 
QDR 4500 fan beam densitometer with software version 
8.21. The characteristics and physical concepts of DXA 
measurements have been described elsewhere.28
Blood Pressure and Arterial Stiffness 
Measurements
Brachial blood pressure (BP) was measured three times in 
a time frame of 15 minutes using a mercury sphygmoman-
ometer in the left arm of the subject, following the stan-
dard methodology suggested by the guidelines. The mean 
of three readings was considered as the subject’s BP. The 
BP was recorded immediately prior to tonometric record-
ing. Subject conditions were standardized according to 
established guidelines: all subjects were fasting, and all 
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subjects had refrained from consumption of alcohol or 
caffeine for the preceding 24 h. MAP was calculated by 
adding 1/3 of the pulse pressure (systolic minus diastolic) 
to the diastolic pressure.
Arterial stiffness was measured non-invasively using 
a small portable device called PulsePen (Diatecne, Milan, 
Italy),29 as previously explained.3 Its software provides 
central aortic pressure values, an assessment of arterial 
pulse wave contours, an estimation of reflection waves 
and measurements of PWV. PulsePen determines the 
PWV by a single probe placed at two sites in rapid succes-
sion, using the ECG trace as reference. The operator starts 
by positioning the probe at the common carotid artery, the 
central detection site, while simultaneously performing 
ECG. Then, the same procedure is followed for the 
femoral artery, in cfPWV, and for the radial artery in the 
crPWV. When the difference between heart rate recorded 
during the carotid measurement and that recorded during 
the femoral or radial measurement was equal to or greater 
than 10%, the PWV measurement was repeated. The dif-
ference in heart rate is indicated by the PulsePen software.
The PWV was calculated as distance between the mea-
surement sites divided by transit time delay between 
femoral and carotid pulse wave and expressed in meters 
per second.
The distance of the pulse wave transit was the differ-
ence between the distance from suprasternal notch to 
femoral point of application of the tonometer and the 
distance from carotid point of tonometer application and 
the suprasternal notch. The time delay was measured 
between the feet of the peripheral artery (femoral or radial) 
and carotid waveforms. The foot of the wave is defined at 
the end of diastole, when the steep rise of the waveform 
begins. The duration of the examination was generally of 
10–15 min for each patient.
Coefficient of variation for cfPWV measured by 
PulsePen device in our laboratory was 6.7%. It was 
obtained by double evaluation in 25 participants.
Biochemical Analyses
Venous blood samples for all metabolic assessments were 
obtained after the subjects fasted overnight. Plasma glu-
cose was measured with a glucose analyzer (Beckman 
Instruments Inc., Palo Alto, CA). The intra-assay CV 
was 1.5%. Cholesterol and triglycerides concentrations 
were determined with an automated enzymatic method 
(Auto analyzer; Technicon, Tarrytown, NY). High- 
density-lipoprotein (HDL) cholesterol was measured by 
using the method of Warnick and Albers. LDL cholesterol 
was calculated using the Friedwald formula. HbA1c was 
measured by high-performance liquid chromatography 
(Bio-Rad Diagnostics Group, Hercules, CA).
Serum leptin and adiponectin were measured using 
specific enzyme-linked immunoassay kits (from DBC- 
Diagnostic Biochem Canada and B-Bridge, respectively). 
The sensitivity of the assays was 0.5 ng/mL for leptin and 
0.02 ng/mL for adiponectin. High-sensitivity C-reactive 
protein (hs-CRP) was measured with the immunoturbidi-
metric method. The detection threshold was 0.5 mg/L, the 
reference interval was 3 mg/L, and analytic variability 
was 5%.
Statistical Analyses
Results are shown as mean ± SD. Variables not normally 
distributed were log-transformed before analysis. 
Pearson’s correlations were used to test the relationship 
between the variables. A subanalysis was done with 2 
groups according to adipokine patterns. Group 1 included 
subjects with high adiponectin levels (3rd tertile) and low 
leptin levels (1st and 2nd tertiles); group 2 included sub-
jects with high leptin levels (3rd tertile) and low adiponec-
tin levels (1st and 2nd tertiles). The analysis of variance 
(ANOVA) was used to compare mean values of cfPWV of 
the groups. A post hoc analysis was used to evaluate the 
differences between the 2 groups.
A backward regression model was used to evaluate the 
joint effect of independent variables on cfPWV. Age, 
gender, MAP, fat mass %, HDL cholesterol, triglycerides 
and adipokine categories were considered as independent 
variables, with cfPWV as the dependent variable. The 
same model was used to perform a binary logistic regres-
sion model to evaluate the joint effect of independent 
variables on subclinical cardiovascular damage, defined 
as cfPWV > 10 m/s values, as previously published.30
A p value of less than 0.05 was considered significant. 
All analyses were performed using SPSS statistical pro-
gram (version 20.0 for Windows).
Results
Main characteristics of the study population are shown in 
Table 1.
Eighty-five elderly patients were evaluated, 58.8% of 
them were women (n=50) and 41.2% men (n=35). The 
mean age was 69.54 ± 4.15 years (range 65–81) and the 
mean BMI was 26.29 ± 3.84 kg/m2 (range 18.83–36.44). 
As high as 64.7% had high cholesterol levels (n=55), 
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15.3% was obese (n=13) and 36.5% was over-
weight (n=31).
Women had a body fat mass percent significantly 
higher than men (36.06±5.07% vs 26.24±5.91%; 
p<0.001). Men had lean body mass significantly higher 
than women (54.33±60.27 kg vs 38.51±50.35 kg; 
p<0.001). Women had leptin and adiponectin values sig-
nificantly higher than men (20.65±13.99 ng/mL vs 9.15 
±8.18 ng/mL; p<0.001 and 17.94±7.04 μg/mL vs 10.04 
±4.45μg/mL; p<0.001, respectively). Total cholesterol and 
HDL cholesterol were significantly higher in women as 
well (222.98±34.52 mg/dL vs 204.85±38.11 mg/dL; 
p=0.02 and 63.67±17.70 mg/dL vs 53.18±14.43 mg/dL; 
p=0.01, respectively). cfPWV resulted significantly higher 
in men than in women (8.67 ± 1.26 m/s vs 7.39 ± 1.16 m/s; 
p<0.01).
In the entire study population significant associations 
were observed between cfPWV and crPWV (r=0.37, 
p=003), age (r=0.27, p=0.02), SBP (r=047, p<001), MAP 
(r=036; p=001), waist circumference (r=026; p=002), fat 
body mass (r=031; p=005) and leptin (r=025; p=004) (data 
not shown in Table).Significant associations were 
observed in women between cfPWV and crPWV (r=032, 
p<005), SBP (r=047, p<001), MAP (r=040; p<001), DBP 
(r=044; p<001), waist circumference (r=031; p<005), fat 
body mass (r=038; p<001) and leptin (r=036; p<005) (data 
not shown in Table), whereas we did not observe 
a significant correlation between cfPWV and Adiponectin 
(r=−016, NS). Significant associations were observed in 
men between cfPWV and age (r=045; p<005), crPWV 
(r=042; p<005), SBP (r=039; p<005), DBP (r=042; 
p<005) and leptin (r=039; p<005) (data not shown in 
Table), whereas we did not observe a significant correla-
tion between cfPWV and Adiponectin.
Table 2 shows a comparison between main anthropo-
metric, metabolic blood pressure and arterial stiffness vari-
ables of the study population divided into two groups: group 
1 with high adiponectin and low leptin, group 2 with high 
leptin and low adiponectin. In group 2, body weight, BMI, 
waist circumference, hip circumference, fat body mass, fat 
body mass percent, and lean body mass were significantly 
higher than in group 1. HDL cholesterol was significantly 
higher in group 1 than in group 2 and triglycerides were 
significantly higher in group 2 than in group 1.
SBP and PP were significantly higher in subjects with 
high leptin and low adiponectin than in which with high 
Table 1 Characteristics of the Study Population







Age (years) 69.54±4.15 69.23±3.80 70.03±4.66 0.37
Body weight (kg) 70.38±13.90 64.85±11.40 78.90±13.19 <0.001
BMI (kg/m2) 26.29±3.84 25.82±3.71 27.02±3.97 0.14
Waist circumference (cm) 88.58±11.75 83.62±9.85 96.42±10.23 <0.001
Hip circumference (cm) 99.76±7.83 99.64±8.32 99.95±7.12 0.85
Fat body mass (kg) 22.44±71.79 23.40±67.42 20.99±76.60 0.11
Fat body mass (%) 32.15±7.24 36.06±5.07 26.24±5.91 <0.001
Lean body mass (kg) 44.80±94.87 38.51±50.35 54.33±60.27 <0.001
Glycemia (mg/dL) 91.97±13.76 92.33±12.07 91.38±16.27 0.75
Total cholesterol (mg/dL) 215.98±36.82 222.98±34.52 204.85±38.11 0.02
HDL cholesterol (mg/dL) 59.61±17.21 63.67±17.70 53.18±14.43 0.01
LDL cholesterol (mg/dL) 135.07±31.02 139.07±30.40 128.70±31.37 0.13
Triglycerides (mg/dL) 104.52±46.31 100.94±45.82 110.21±47.20 0.36
Glycated Hemoglobin (%) 5.72±0.33 5.80±0.30 5.59±0.34 0.01
SBP (mmHg) 147.50±19.78 144.84±19.40 151.46±19.95 0.12
DBP (mmHg) 84.04±8.96 83.02±9.25 85.57±8.41 0.18
PP (mm Hg) 63.46±15.85 61.82±15.71 65.89±15.95 0.23
MBP (mmHg) 105.20±11.32 103.62±11.30 107.53±11.10 0.11
cf PWV (m/s) 10.27±2.44 7.93±1.16 8.67±1.26 0.01
cr PWV (m/s) 8.21±1.25 10.15±2.32 10.47±2.64 0.59
Leptin (ng/mL) 15.92±13.18 20.65±13.99 9.15±8.18 <0.001
Adiponectin (μg/mL) 14.74±7.23 17.94±7.04 10.04±4.45 <0.001
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adiponectin and low leptin. Also cfPWV was significantly 
higher in group 2 than in group 1 (1204 ± 239 m/s vs 879 
± 163 m/s; p<0001). cr PWV was not significantly differ-
ent in 2 groups of study.
In Figure 1, cfPWV values stratified for adipokine 
categories, after adjustment for gender, fat body 
mass percent, MBP, HDL cholesterol, and triglycerides 
are shown. After adjustment for these covariates, patients 
in the group with high leptin and low adiponectin 
(group 2) showed still higher cfPWV than patients in the 
group with high adiponectin and low leptin (1186 ± 
069 m/s vs 999 ± 069 m/s; p=002).
Table 3 shows a backward multiple regression model 
considering cfPWV as dependent variable and age, gender, 
MAP, HDL cholesterol, triglycerides, fat body 
mass percent, adipokine category as independent variables. 
Age, MAP, triglycerides and the category with high leptin 
and low adiponectin resulted to be significant predictors of 
cfPWV and explains 35.6% of variance.
In Table 4, a binary logistic regression model is shown that 
considers subclinical vascular damage (considered as 
cfPWV>10 m/s) as a dependent variable and age, gender, 
MAP, fat body mass percent, triglycerides, HDL cholesterol 
and the category with high leptin and low adiponectin as 
independent variables. MAP and the category of patients 
with high leptin and low adiponectin resulted significant pre-
dictors of subclinical vascular damage with an OR, respec-
tively, 1.09 (CI 103–116; p=001) and 361 (CI 119–1100; 
p=002).
Discussion
This study shows an association between adipokines and 
arterial stiffness in a population of elderly patients with 
unknown cardiovascular disease, showing that the simul-
taneous presence of high leptin levels and low adiponectin 
levels have a synergic effect on development of subclinical 
vascular damage and increases the risk by 3.6 times.
In our study, there was a significant association 
between leptin and arterial stiffness in both genders 
(r=0.39 men, r=0.36 in women; p<0.05). These results 
confirmed previous studies in younger populations. 
Singhal et al showed an association between leptin and 
cfPWV in a group of 294 healthy adolescents who had 
a broad range of BMI, independently of fat body mass, 
blood pressure and CRP, suggesting high leptin concentra-
tion as an important mechanism for arterial stiffness and 
left ventricular hypertrophy observed in these patients.31
It has been shown that serum leptin levels are posi-
tively correlated with cardiovascular risk independently of 
fat body mass; indeed, higher serum leptin levels were 
shown in both women and men with myocardial infarc-
tion, independently of traditional risk factors and obesity.32
Experimental studies suggest different mechanisms by 
which leptin might promote arterial stiffness. Even if 
known central hypothalamic effects of leptin include 
food intake reduction and increasing energy expenditure, 
leptin receptors have been found in the heart, vessels, and 
mainly in the aorta.33 Other receptors are also present in 
tunica media and adventitia of arteries and inside of ather-
osclerotic plaques.34,35 Leptin, through these receptors, 
could promote vascular smooth muscle cell proliferation 
and migration contributing to arterial stiffness.18 
Furthermore, treatment with leptin has been shown in 
mice to increase artery calcification.34 Moreover, previous 
in vitro and human studies showed that leptin also induces 
Table 2 Comparison Between Main Anthropometric, Metabolic 
and Cardiovascular Variables of the Study Population Divided 
into Two Groups: Group 1 with High Adiponectin (3rd Tertile) 
and Low Leptin (1st and 2nd Tertile); Group 2 with High Leptin 
























Hip circumference (cm) 94.92±6.97 107.00±5.30 <0.001
Fat body mass (kg) 18.43±46.47 30.49±50.29 <0.001
Fat body mass % 31.81±5.05 38.84±4.13 <0.001
Lean body mass (kg) 37.07±38.84 46.05±90.53 <0.001
Glycemia (mg/dL) 90.93±7.69 92.89±17.97 0.70
Tot cholesterol (mg/dL) 225.93±28.12 223.06±28.77 0.77
HDL cholesterol (mg/dL) 77.00±21.98 54.06±11.06 <0.001
LDL cholesterol (mg/dl) 133.73±25.38 145.39±25.76 0.20
Triglycerides (mg/dl) 75.67±27.22 117.17±44.58 0.01
SBP (mmHg) 138.88±14.52 155.82±21.26 0.01
DBP (mmHg) 81.94±8.44 85.12±9.82 0.32
PP (mmHg) 56.94±9.02 70.71±14.10 0.01
MBP (mmHg) 100.92±9.99 108.69±13.07 0.06
cf PWV (m/s) 8.79±1.63 12.04±2.39 <0.001
cr PWV (m/s) 8.00±1.15 8.22±1.43 0.66
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; MBP, mean blood pressure; PP, pulse pressure; cf PWV, carotid 
femoral pulse wave velocity; cr PWV, carotid radial pulse wave velocity; NS, not 
significant.
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endothelial oxidative stress and reactive oxygen species 
formation.19,35
The most important result of our study is the synergic 
effect between the presence of both low adiponectin and 
high leptin levels on vascular damage. When we divided 
the study population according to adipokine patterns, 
cfPWV was higher in subjects with high leptin and low 
adiponectin than subjects with high adiponectin and low 
leptin, even after adjustment for gender, fat mass percent, 
MAP, HDL cholesterol, and triglycerides. We adjusted 
the values for these variables because there was a sig-
nificant difference between the 2 groups. We decided to 
adjust for fat mass percent instead of BMI because it is 
widely known that the FM % evaluated by DXA is much 
more precise than BMI in predicting the quantity of 
adipose tissue.
Furthermore, in a model of binary logistic regression 
where subclinical vascular damage was considered as the 
dependent variable and gender, MBP, triglycerides, HDL 
cholesterol, low leptin/high adiponectin category as indepen-
dent variables, this adverse adipokine pattern increased the 























































Figure 1 Carotid-femoral pulse wave velocity values in different study groups before (red columns) and after (blue columns) adjustment for gender, fat mass%, MBP, HDL 
cholesterol and triglycerides.
Table 3 Backward Multiple Regression Considering PWVcf as 
Dependent Variable and Age, Gender, MBP, HDL Cholesterol, 
Triglycerides, Fat Body Mass Percent, Adipokines Category as 
Independent Variables, in the Complete Study Population (n=85)




High leptin and low adiponectin 0.26 0.02 0.356
Abbreviations: MBP, mean blood pressure; HDL, high-density lipoprotein.
Table 4 Binary Logistic Regression Considering Subclinic 
Vascular Damage (Cf PWF>10 m/s) as Dependent Variable and 
Age, Gender, MBP, Fat Body Mass Percent, Triglycerides, HDL 
Cholesterol and the Category with High Leptin and Low 




SE OR CI p
Age 0.121 0.07 1.13 0.99–1.29 0.07
Gender −0.20 1.00 1.14 0.02–1.01 0.051
MBP 0.09 0.03 1.09 1.03–1.16 0.01
HDL Cholesterol −0.02 0.02 0.98 0.95–1.02 0.42
Triglycerides −0.06 0.01 0.99 0.98–1.01 0.47
Fat body mass % −0.12 0.07 0.88 0.77–1.02 0.08
High leptin and 
low adiponectin
1.28 0.568 3.61 1.19–11.00 0.02
Abbreviations: MBP, mean blood pressure; HDL, High-Density Lipoprotein.
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Previously, Windham et al, in 749 individual ages 
26–96 years with mean BMI 26.6 kg/m2, showed that 
high leptin and low adiponectin were independently asso-
ciated with cfPWV.21 These cytokines show a competitive 
effect on the vascular wall: the inflammatory activity of 
leptin is balanced with the anti-inflammatory activity of 
adiponectin. Furthermore, adiponectin seems to inhibit the 
remodelling of vascular extracellular matrix promoted by 
leptin which induces vessel fibrosis and thereby leads to 
arterial stiffness.36
In addition to the vascular effect, overweight and obese 
individuals with a higher ratio of adiponectin/leptin have 
a better metabolic profile.37 This protective adipokine pro-
file is therefore related to a positive hemodynamic and 
metabolic pattern promoting longevity. Indeed, it was 
shown that centenarians have higher adiponectin levels 
and lower leptin levels than control individuals.38
While the majority of previous studies were conducted 
on patient populations with already known cardiovascular 
risk factors, our results were obtained from a elderly popu-
lation, without diabetes and known cardiovascular dis-
eases, and therefore without any medical therapies that 
could influence arterial stiffness. Actually we found some 
not known hypertensive subjects evaluating the study 
population and since hypertension is a known major deter-
minant of arterial stiffness we adjusted the cfPWV data 
even for MBP comparing the group with different adipo-
kines profile, finding significant differences between the 2 
groups even after this adjustment.
In this way, a negative adipokine profile could be 
considered as a predisposing factor for arterial stiffness 
and consequently for cardiovascular disease, and this pro-
file is recognizable at a very early stage and before the 
appearance of vascular damage.
We did not find a direct significant correlation between 
adiponectin and cfPWV, probably because of the small 
number of our study population. Several studies in wider 
populations showed a negative association between arterial 
stiffness and serum adiponectin concentration in healthy 
populations but even in hypertensive, diabetic and metabolic 
syndrome patients.20,29,39–43 El Khoudary et al showed that 
baseline adiponectin levels were independent predictors of 
aortic stiffness progression in a population of 240 men 
(40–49 years old) free of cardiovascular disease.27
In vitro studies highlighted the role of adiponectin on 
vascular tone regulation by increasing nitric oxide in 
endothelial cells.44 In addition, adiponectin may be 
involved in the repair of injured vessels: it was found in 
the subendothelial space of carotid arteries damaged by 
a catheter and in the endothelium of atherosclerotic 
vessels24 and it may prevent vascular stenosis.23
Some limitations of this study should be recognized. 
There was a lack of data regarding inflammation markers 
in order to analyse a possible link between abdominal 
adiposity, adipokines and vascular damage. We only eval-
uated 2 adipokines and probably the assessment of some 
others adipokines could have helped to better understand 
the relationships between VAT and arterial stiffness. We 
recruited just Caucasian elderly subjects without high 
comorbidity and this could be a limitation to interpret 
and generalize the findings. Study sample was small and 
for this reason we could not have found some significant 
differences for study variables with low effect size.
In conclusion, in this study analysing the association 
between adipokines and arterial stiffness in a group of 
elderly subjects, we found that low serum leptin level 
and high serum adiponectin level with triglycerides, 
MBP and age are predictors of arterial stiffness. 
Moreover, the simultaneous presence of high leptin levels 
and low adiponectin levels seems to have a synergic effect 
on development of subclinical vascular damage increasing 
the risk by 36 times.
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